At	(O,|)
present	(O,|)
,	(O,|)
a	(O,|)
large	(O,|)
number	(O,|)
of	(O,|)
patients	(O,|)
in	(O,|)
poor	(O,|)
countries	(O,|)
are	(O,|)
suffering	(O,|)
from	(O,|)
deaths	(O,|)
caused	(O,|)
by	(O,|)
lack	(O,|)
of	(O,|)
medication	(O,|)
rather	(O,|)
than	(O,|)
dangerous	(O,|)
diseases	(O,|)
.	(O,|)
It	(O,|)
is	(O,|)
suggested	(O,|)
that	(O,|)
companies	(O,|)
in	(O,|)
developed	(O,|)
countries	(O,|)
ought	(O,|)
to	(O,|)
reduce	(O,|)
their	(O,|)
price	(O,|)
of	(O,|)
medicines	(O,|)
to	(O,|)
avoid	(O,|)
such	(O,|)
unnecessary	(O,|)
deaths	(O,|)
.	(O,|)
Admittedly	(O,|)
,	(O,|)
more	(P,67)
lives	(I,66)
will	(I,65)
be	(I,64)
saved	(I,63)
by	(I,62)
the	(I,61)
use	(I,60)
of	(I,59)
effective	(I,58)
medicines	(I,57)
.	(O,|)
The	(P,55)
medical	(I,54)
industry	(I,53)
in	(I,52)
developing	(I,51)
countries	(I,50)
is	(I,49)
incapable	(I,48)
of	(I,47)
producing	(I,46)
high-quality	(I,45)
drugs	(I,44)
.	(O,|)
With	(P,42)
advanced	(I,41)
technology	(I,40)
,	(I,39)
the	(I,38)
developed	(I,37)
world	(I,36)
has	(I,35)
achieved	(I,34)
remarkable	(I,33)
breakthroughs	(I,32)
in	(I,31)
making	(I,30)
medicines	(I,29)
,	(I,28)
which	(I,27)
can	(I,26)
cure	(I,25)
a	(I,24)
variety	(I,23)
of	(I,22)
serious	(I,21)
illnesses	(I,20)
.	(O,|)
If	(P,18)
people	(I,17)
in	(I,16)
poorer	(I,15)
countries	(I,14)
gain	(I,13)
access	(I,12)
to	(I,11)
these	(I,10)
drugs	(I,9)
,	(I,8)
their	(I,7)
health	(I,6)
situations	(I,5)
may	(I,4)
be	(I,3)
better	(I,2)
.	(O,|)
The	(C,0)
reduction	(I,0)
in	(I,0)
cost	(I,0)
of	(I,0)
medicines	(I,0)
therefore	(I,0)
shows	(I,0)
the	(I,0)
sign	(I,0)
of	(I,0)
humanity	(I,0)
.	(O,|)
However	(O,|)
,	(O,|)
the	(O,|)
current	(O,|)
cost	(O,|)
of	(O,|)
medicines	(O,|)
is	(O,|)
,	(O,|)
in	(O,|)
fact	(O,|)
,	(O,|)
reasonable	(O,|)
and	(O,|)
based	(O,|)
on	(O,|)
the	(O,|)
medicines'	(O,|)
effectiveness	(O,|)
.	(O,|)
Apparently	(O,|)
,	(O,|)
the	(P,137)
process	(I,136)
of	(I,135)
researching	(I,134)
,	(I,133)
testing	(I,132)
and	(I,131)
producing	(I,130)
drugs	(I,129)
in	(I,128)
masses	(I,127)
costs	(I,126)
a	(I,125)
substantial	(I,124)
amount	(I,123)
of	(I,122)
money	(I,121)
.	(O,|)
Moreover	(O,|)
,	(O,|)
these	(P,37)
products	(I,36)
prove	(I,35)
to	(I,34)
ensure	(I,33)
human	(I,32)
health	(I,31)
completely	(I,30)
.	(O,|)
Suppose	(P,28)
companies	(I,27)
were	(I,26)
forced	(I,25)
to	(I,24)
reduce	(I,23)
the	(I,22)
cost	(I,21)
of	(I,20)
drugs	(I,19)
,	(I,18)
they	(I,17)
would	(I,16)
make	(I,15)
no	(I,14)
profit	(I,13)
,	(I,12)
even	(I,11)
running	(I,10)
up	(I,9)
debt	(I,8)
because	(I,7)
of	(I,6)
production	(I,5)
expenditure	(I,4)
.	(O,|)
Therefore	(O,|)
,	(O,|)
the	(C,0)
measure	(I,0)
cannot	(I,0)
be	(I,0)
adopted	(I,0)
,	(I,0)
otherwise	(I,0)
those	(I,0)
companies	(I,0)
will	(I,0)
go	(I,0)
into	(I,0)
liquidation	(I,0)
.	(O,|)
In	(O,|)
short	(O,|)
,	(O,|)
this	(O,|)
is	(O,|)
not	(O,|)
a	(O,|)
long-term	(O,|)
solution	(O,|)
.	(O,|)
Fortunately	(O,|)
,	(O,|)
there	(C,9)
are	(I,8)
other	(I,7)
measures	(I,6)
to	(I,5)
improve	(I,4)
the	(I,3)
situation	(I,2)
.	(O,|)
It	(P,45)
is	(I,44)
advisable	(I,43)
for	(I,42)
the	(I,41)
government	(I,40)
to	(I,39)
encourage	(I,38)
medical	(I,37)
production	(I,36)
by	(I,35)
supplying	(I,34)
land	(I,33)
for	(I,32)
building	(I,31)
factories	(I,30)
and	(I,29)
reducing	(I,28)
part	(I,27)
of	(I,26)
the	(I,25)
taxes	(I,24)
.	(O,|)
Additionally	(O,|)
,	(O,|)
charitable	(P,20)
organizations	(I,19)
can	(I,18)
buy	(I,17)
medicines	(I,16)
from	(I,15)
developed	(I,14)
countries	(I,13)
and	(I,12)
distribute	(I,11)
to	(I,10)
the	(I,9)
undeveloped	(I,8)
world	(I,7)
for	(I,6)
free	(I,5)
.	(O,|)
In	(O,|)
conclusion	(O,|)
,	(O,|)
I	(C,0)
disagree	(I,0)
with	(I,0)
reducing	(I,0)
the	(I,0)
cost	(I,0)
of	(I,0)
medicines	(I,0)
,	(I,0)
which	(I,0)
may	(I,0)
exacerbate	(I,0)
their	(I,0)
qualities	(I,0)
.	(O,|)
Instead	(O,|)
,	(O,|)
the	(O,|)
government	(O,|)
and	(O,|)
medical	(O,|)
foundations	(O,|)
should	(O,|)
be	(O,|)
responsible	(O,|)
for	(O,|)
the	(O,|)
distribution	(O,|)
of	(O,|)
drugs	(O,|)
to	(O,|)
the	(O,|)
undeveloped	(O,|)
world	(O,|)
at	(O,|)
a	(O,|)
more	(O,|)
reasonable	(O,|)
price	(O,|)
.	(O,|)
